The significance of the site of recurrence to subsequent breast cancer survival

被引:33
作者
Imkampe, A. [1 ]
Bendall, S. [1 ]
Bates, T. [1 ]
机构
[1] William Harvey Hosp, Breast Unit, Ashford TN24 0LZ, Kent, England
来源
EJSO | 2007年 / 33卷 / 04期
关键词
recurrent breast cancer; survival; recurrence site; ADJUVANT CHEMOTHERAPY; PROGNOSTIC-FACTORS; 1ST RECURRENCE; CLINICAL-COURSE; THERAPY; PATTERN;
D O I
10.1016/j.ejso.2006.09.005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: To investigate differences in the 3-year survival of patients with recurrent breast cancer dependent on recurrence site. Methods: The study was a review of 294 patients from a breast cancer database, who were treated for operable breast cancer and subsequently developed a recurrence between 1989 and 2003. Patients were divided into four groups according to the site of first recurrence (local, lymph node, bone or visceral). Breast Cancer Specific Survival (BCSS) was compared using Kaplan-Meier life table analysis and the log rank test. Results: Patient and tumour characteristics were comparable between the four groups. Survival rates between the recurrence site groups were significantly different. Patients in whom first recurrence was local had the best prognosis with a 3-year BCSS of 83% compared to 33% for patients with first node recurrence (p < 0.001), 23% for patients with first bone recurrence (p = 0.03) and 13% for patients with first visceral recurrence (p = 0.004). Conclusion: Survival of patients with recurrent breast cancer is associated with the site of first recurrence. The prognosis from recurrence is progressively worse with local, regional, bone and visceral metastasis. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:420 / 423
页数:4
相关论文
共 20 条
[1]  
Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0
[2]   THE EFFECT OF PRIOR ADJUVANT CHEMOTHERAPY ON SURVIVAL IN METASTATIC BREAST-CANCER [J].
AHMANN, FR ;
JONES, SE ;
MOON, TE .
JOURNAL OF SURGICAL ONCOLOGY, 1988, 37 (02) :116-122
[3]   RESULTS OF SALVAGE HORMONAL-THERAPY AND SALVAGE CHEMOTHERAPY IN WOMEN FAILING ADJUVANT CHEMOTHERAPY AFTER MASTECTOMY FOR BREAST-CANCER [J].
BUCKNER, JC ;
INGLE, JN ;
EVERSON, LK ;
OFALLON, JR ;
CULLINAN, SA ;
AHMANN, DL ;
KROOK, JE ;
PFEIFLE, DM .
BREAST CANCER RESEARCH AND TREATMENT, 1989, 13 (02) :135-142
[4]   Retreating recurrent breast cancer with the same CMF-containing regimen used as adjuvant therapy [J].
Castiglione-Gertsch, M ;
Tattersall, M ;
Hacking, A ;
Goldhirsch, A ;
Gudgeon, A ;
Gelber, RD ;
Lindtner, J ;
Coates, A ;
Collins, J ;
Isley, M ;
Senn, HJ ;
Rudenstam, CM .
EUROPEAN JOURNAL OF CANCER, 1997, 33 (14) :2321-2325
[5]   Survival of patients with metastatic breast carcinoma - Importance of prognostic markers of the primary tumor [J].
Chang, J ;
Clark, GM ;
Allred, DC ;
Mohsin, S ;
Chamness, G ;
Elledge, RM .
CANCER, 2003, 97 (03) :545-553
[6]   SURVIVAL FROM 1ST RECURRENCE - RELATIVE IMPORTANCE OF PROGNOSTIC FACTORS IN 1,015 BREAST-CANCER PATIENTS [J].
CLARK, GM ;
SLEDGE, GW ;
OSBORNE, CK ;
MCGUIRE, WL .
JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (01) :55-61
[7]   Clinical course and prognostic factors following bone recurrence from breast cancer [J].
Coleman, RE ;
Smith, P ;
Rubens, RD .
BRITISH JOURNAL OF CANCER, 1998, 77 (02) :336-340
[8]   Local recurrence in breast cancer: Implications for systemic disease [J].
Curcio, LD ;
Chu, DZJ ;
Ahn, C ;
Williams, WL ;
Paz, B ;
Riihimaki, D ;
Ellenhorn, JDI ;
Wagman, L .
ANNALS OF SURGICAL ONCOLOGY, 1997, 4 (01) :24-27
[9]   POSSIBLE ADVERSE EFFECT OF FAILED ADJUVANT CHEMOTHERAPY ON THE PROGNOSIS OF WOMEN RECEIVING CONSECUTIVE CHEMOTHERAPY FOR RECURRENT BREAST-CANCER [J].
DITTRICH, C ;
JAKESZ, R ;
PIRICH, K ;
HAVELEC, L ;
STEGER, G ;
SCHLAPPACK, O ;
KOLB, R ;
MOSER, K .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1987, 113 (05) :488-494
[10]   Is breast cancer survival improving? Trends in survival for patients with recurrent breast cancer diagnosed from 1974 through 2000 [J].
Giordano, SH ;
Buzdar, AU ;
Smith, TL ;
Kau, SW ;
Yang, Y ;
Hortobagyi, GN .
CANCER, 2004, 100 (01) :44-52